Is Gain Therapeutics, Inc. (GANX) a Buy, Sell, or Hold?
Gain Therapeutics, Inc.
NASDAQ:GANX
$1.68 USD
-$0.08 (-4.55%)
- Volume
- 1.47M
- Average Volume
- 865.44K
- Market Capitalization
- $71.66M
- P/E Ratio
- -2.90
- Dividend Yield
- 0.00%
- Price Target
- $8.00
- Year High
- $4.34
- Year Low
- $1.41
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.69
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Gene Mack |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GANX |
| CUSIP | 36269B105 |
| CIK | 0001819411 |
| Web | https://www.gaintherapeutics.com |
| Phone | 301 500 1556 |
| Currency | USD |
| Employees | 21 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.05 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.69 |
| Quick Ratio | 4.69 |
| Cash Ratio | 4.26 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.46 |
| Price / Cash Flow | -3.70 |
| Price / Book | 5.07 |
Price Target and Rating
| Average Stock Price Forecast | $8.00 |
| High Stock Price Forecast | $10.00 |
| Low Stock Price Forecast | $4.00 |
| Forecast Upside/Downside | -79.00% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.61 |
| Trailing P/E Ratio | -2.90 |
| PEG Ratio | -0.07 |
| P/E Growth | -0.07 |
| Net Income | $-20.16M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -201.43% |
| Return on Assets | -113.35% |
Financials Score
| AltmanZ Score | -1.16 |
| Piotroski Score | 3.00 |
| Working Capital | 14.34M |
| Total Assets | 18.74M |
| Ebit | -20.3M |
| Market Cap | 74.86M |
| Total Liabilities | 4.73M |
Poll Results
About Gain Therapeutics, Inc. (NASDAQ:GANX) Stock
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher d ... isease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
2026-06-29 16:05:00
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
2026-06-10 07:00:00
BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held in a hybrid format from June 15-16, 2026.
2026-05-26 08:00:00
MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150 Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait BETHESDA, Md., May 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of an oral presentation at the 3rd International GBA1 Meeting 2026, held May 22-23, 2026, in Phoenix, AZ.
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
2026-05-11 07:00:00
BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
2026-04-24 08:30:00
BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the 3rd International GBA1 Meeting 2026, being held May 22-23, 2026, in Phoenix, AZ.
Frequently Asked Questions
-
What is the current Gain Therapeutics, Inc. (GANX) stock price?
-
Gain Therapeutics, Inc.(NASDAQ:GANX) stock price is $1.68 in the last trading session. During the trading session, GANX stock reached the peak price of $4.34 while $1.41 was the lowest point it dropped to. The percentage change in GANX stock occurred in the recent session was --4.55% while the dollar amount for the price change in GANX stock was -$-0.08.
-
GANX's industry and sector of operation?
-
The NASDAQ listed GANX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GANX?
-
Khalid Islam | Chairman & Founder
Terenzio Ignoni | Senior Vice President of Technical Operations
Gene Mack | President, Chief Executive Officer & Director
Joanne Taylor | Senior Vice President of Research
Jonas Hannestad | Chief Medical Officer -
How many employees does GANX have?
-
Number of GANX employees currently stands at 21. GANX operates from 4800 Montgomery Lane, Bethesda, MD 20814, US.
-
Link for GANX official website?
-
Official Website of GANX is: https://www.gaintherapeutics.com
-
How do I contact GANX?
-
GANX could be contacted at phone #301 500 1556 and can also be accessed through its website. GANX operates from 4800 Montgomery Lane, Bethesda, MD 20814, US.
-
How many shares of GANX are traded daily?
-
The average number of GANX shares traded daily for last 3 months was 865.44K.
-
What is the market cap of GANX currently?
-
The market value of GANX currently stands at $71.66M with its latest stock price at $1.68